MétaCan
Menu
← Back to cohort

Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome

2005· article· en· W86002999 on OpenAlexaff
Allan Lipton, Y. Hei, RE Coleman, Pierre Major, Richard J. Cook

Bibliographic record

VenueJournal of Clinical Oncology · 2005
Typearticle
Languageen
FieldMedicine
TopicBone health and treatments
Canadian institutionsHamilton Regional Laboratory Medicine Program
Fundersnot available
KeywordsMedicineZoledronic acidN-terminal telopeptideCreatinineInternal medicineMultiple myelomaUrinary systemBone remodelingBreast cancerBone resorptionUrologyCancerGastroenterologyEndocrinologyAlkaline phosphataseOsteocalcin

Abstract

fetched live from OpenAlex

532 The bone resorption marker N-telopeptide (Ntx) provides valuable prognostic information in patients with bone metastases. Across all tumor types an elevated baseline Ntx increases the relative risk of skeletal-related events (SREs), disease progression and death (Brown, et al., ASCO 2003). In this study, urinary N-telopeptide was measured at baseline and at month 3 in 290 patients with breast cancer and multiple myeloma treated with monthly 4 mg of zoledronic acid. At baseline, 120 patients had a urinary Ntx value of 0–64 nmol/mmol creatinine (upper limit of normal for premenopausal women) and 170 had an elevated baseline Ntx (greater than 64 nmol/mmol creatinine). At month 3 of zoledronic acid treatment, only 2/120 (1.7%) patients who started with normal Ntx developed an elevated value. At month 3, 137/170 (80.6%) of patients who began treatment with elevated Ntx had a normal Ntx, 26/170 (15.3%) had persistent elevation of Ntx, and 7/170 (4.1%) patients died. A persistently elevated Ntx (greater than 64 nmol/mmol creatinine) was a significant predictor of subsequently developing a first SRE (RR = 1.71; p = 0.035) and SRE-free survival (RR = 1.65; p = 0.039). It did not predict time to progression of cancer in the skeleton (RR = 1.26; p = 0.417) or survival (RR = 1.33, p = 0.316). In summary, in breast cancer and multiple myeloma patients, normalization of an elevated baseline urinary Ntx at month 3 of treatment with zoledronic acid is a significant predictor of favorable outcome as measured by SREs and time to first SRE. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis Novartis Novartis Novartis Novartis Novartis

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.085
GPT teacher head0.484
Teacher spread0.399 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2005
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicBone health and treatments→French-language works237,207→